Get started
Author

Takeshi Tsuda

Observed names: T. Tsuda, T., Tsuda, TAKESHI TSUDA, Tsuda, Takeshi
ORCID: 0000-0003-2308-748X
Observed ORCIDs: 0000-0003-2308-748X, 0000-0002-6243-4459
OpenAlex ID: A5103197306
Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study
2015 · Kensuke Suzuki, Hideaki Furuse, et al. · Journal of International Medical Research · 50
PDF
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
2018 · Hisao Imai, Kyoichi Kaira, et al. · Lung Cancer · 49
Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
2022 · Ayako Shiono, Hisao Imai, et al. · Cancer Medicine · 36
PDF
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
2024 · Naoya Nishioka, Hisao Imai, et al. · Targeted Oncology · 21
PDF
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice
2023 · Minehiko Inomata, Takeshi Tsuda, et al. · Thoracic Cancer · 17
PDF
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
2022 · Hisao Imai, Yoshiaki Nagai, et al. · Investigational New Drugs · 16
PDF
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
2023 · Hisao Imai, Satoshi Wasamoto, et al. · Thoracic Cancer · 12
PDF
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
2022 · Ken Masubuchi, Hisao Imai, et al. · Thoracic Cancer · 12
Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data
2020 · Kentaro Ito, Kenta Murotani, et al. · Cancer Science · 11
PDF
Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC
2018 · K. Ito, K. Murotani, et al. · Annals of Oncology · 9
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
2022 · Hisashi Tanaka, Shigeru Tanzawa, et al. · Therapeutic Advances in Medical Oncology · 8
Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer
2024 · Satoshi Wasamoto, Hisao Imai, et al. · Internal Medicine · 7
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
2021 · Yuko Oya, Tatsuya Yoshida, et al. · BMC Cancer · 7
PDF
Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study
2022 · Takeshi Tsuda, Naoki Takata, et al. · Case Reports in Oncology · 6
Bronchial biopsy and reactivity in patients with chest tightness relieved with bronchodilator
2016 · Hirokazu Taniguchi, Hideaki Furuse, et al. · Journal of Asthma · 6
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
2024 · Takeshi Tsuda, Tomomi Ichikawa, et al. · Discover Oncology · 5
PDF
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
2023 · Takeshi Tsuda, Hisao Imai, et al. · Oncology Letters · 5
PDF
Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective study
2014 · Kensuke Suzuki, Tomomi Ichikawa, et al. · Supportive Care in Cancer · 4
Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
2023 · Yasushi Goto, Kodai Kawamura, et al. · Current Therapeutic Research · 3
Multimodal imaging findings in an adult case of Swyer‐James‐MacLeod syndrome
2017 · Hitoshi Kawasuji, Kensuke Suzuki, et al. · Respirology Case Reports · 3
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
2022 · Shigeru Tanzawa, Tomonori Makiguchi, et al. · Therapeutic Advances in Medical Oncology · 2
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
2021 · Shigeru Tanzawa, Sunao Ushijima, et al. · Therapeutic Advances in Medical Oncology · 2
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non–small cell lung cancer: exploratory analysis of a prospective observational study
2026 · Takashi Kurosaki, Shinichiro Suzuki, et al. · Lung Cancer · 1
Nivolumab-related encephalitis with extensive cortical–subcortical involvement
2026 · Kei Matsuyama, Keisuke Shima, et al. · Rinsho Shinkeigaku · 1
PDF
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens
2025 · MINEHIKO INOMATA, TAKESHI TSUDA, et al. · Cancer Diagnosis & Prognosis · 1
PDF
Works count: 50
Citation count: 296
H-index: 9
I10-index: 9
Year
Topic
Type